Systems biology strategy reveals PKCd is key for sensitizing TRAIL-resistant human fibrosarcoma

Kentaro Hayashi, Sho Tabata, Vincent Piras, Masaru Tomita, Kumar Selvarajoo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently, the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced treatment is gaining momentum due to TRAIL's ability to specifically target cancers with limited effect on normal cells. Nevertheless, several malignant cancer types still remain non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based on perturbation-response differential equations approach, and predicted protein kinase C (PKC) as the most effective target, with over 95% capacity to kill human fibrosarcoma (HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has significant implications for cancer treatment, we conducted experiments on two TRAIL-resistant cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demonstrated that cell viability is significantly impaired with over 95% death of both cancer types, in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose) polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down (KD) experiments. From these KDs, PKCd produced the most cancer cell death in conjunction with TRAIL. Overall, our approach combining model predictions with experimental validation holds promise for systems biology based cancer therapy.

Original languageEnglish
Article number00659
JournalFrontiers in Immunology
Volume6
Issue numberJAN
DOIs
Publication statusPublished - 2015

Fingerprint

Systems Biology
Fibrosarcoma
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Neoplasms
Protein Kinase C
Poly(ADP-ribose) Polymerases
Caspase 3
Cell Death
RNA Isoforms
Protein C Inhibitor
Protein Kinase Inhibitors
Small Interfering RNA
Cell Survival
Protein Isoforms
Cell Line
Therapeutics

Keywords

  • Apoptosis
  • Cancer
  • Cell dynamics
  • Computational model
  • Protein kinase C
  • Signaling pathway
  • TRAIL

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Systems biology strategy reveals PKCd is key for sensitizing TRAIL-resistant human fibrosarcoma. / Hayashi, Kentaro; Tabata, Sho; Piras, Vincent; Tomita, Masaru; Selvarajoo, Kumar.

In: Frontiers in Immunology, Vol. 6, No. JAN, 00659, 2015.

Research output: Contribution to journalArticle

Hayashi, Kentaro ; Tabata, Sho ; Piras, Vincent ; Tomita, Masaru ; Selvarajoo, Kumar. / Systems biology strategy reveals PKCd is key for sensitizing TRAIL-resistant human fibrosarcoma. In: Frontiers in Immunology. 2015 ; Vol. 6, No. JAN.
@article{37f72aa86b714580b753399b452333f1,
title = "Systems biology strategy reveals PKCd is key for sensitizing TRAIL-resistant human fibrosarcoma",
abstract = "Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently, the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced treatment is gaining momentum due to TRAIL's ability to specifically target cancers with limited effect on normal cells. Nevertheless, several malignant cancer types still remain non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based on perturbation-response differential equations approach, and predicted protein kinase C (PKC) as the most effective target, with over 95{\%} capacity to kill human fibrosarcoma (HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has significant implications for cancer treatment, we conducted experiments on two TRAIL-resistant cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demonstrated that cell viability is significantly impaired with over 95{\%} death of both cancer types, in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose) polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down (KD) experiments. From these KDs, PKCd produced the most cancer cell death in conjunction with TRAIL. Overall, our approach combining model predictions with experimental validation holds promise for systems biology based cancer therapy.",
keywords = "Apoptosis, Cancer, Cell dynamics, Computational model, Protein kinase C, Signaling pathway, TRAIL",
author = "Kentaro Hayashi and Sho Tabata and Vincent Piras and Masaru Tomita and Kumar Selvarajoo",
year = "2015",
doi = "10.3389/fimmu.2014.00659",
language = "English",
volume = "6",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Systems biology strategy reveals PKCd is key for sensitizing TRAIL-resistant human fibrosarcoma

AU - Hayashi, Kentaro

AU - Tabata, Sho

AU - Piras, Vincent

AU - Tomita, Masaru

AU - Selvarajoo, Kumar

PY - 2015

Y1 - 2015

N2 - Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently, the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced treatment is gaining momentum due to TRAIL's ability to specifically target cancers with limited effect on normal cells. Nevertheless, several malignant cancer types still remain non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based on perturbation-response differential equations approach, and predicted protein kinase C (PKC) as the most effective target, with over 95% capacity to kill human fibrosarcoma (HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has significant implications for cancer treatment, we conducted experiments on two TRAIL-resistant cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demonstrated that cell viability is significantly impaired with over 95% death of both cancer types, in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose) polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down (KD) experiments. From these KDs, PKCd produced the most cancer cell death in conjunction with TRAIL. Overall, our approach combining model predictions with experimental validation holds promise for systems biology based cancer therapy.

AB - Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently, the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced treatment is gaining momentum due to TRAIL's ability to specifically target cancers with limited effect on normal cells. Nevertheless, several malignant cancer types still remain non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based on perturbation-response differential equations approach, and predicted protein kinase C (PKC) as the most effective target, with over 95% capacity to kill human fibrosarcoma (HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has significant implications for cancer treatment, we conducted experiments on two TRAIL-resistant cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demonstrated that cell viability is significantly impaired with over 95% death of both cancer types, in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose) polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down (KD) experiments. From these KDs, PKCd produced the most cancer cell death in conjunction with TRAIL. Overall, our approach combining model predictions with experimental validation holds promise for systems biology based cancer therapy.

KW - Apoptosis

KW - Cancer

KW - Cell dynamics

KW - Computational model

KW - Protein kinase C

KW - Signaling pathway

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=84926609176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926609176&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2014.00659

DO - 10.3389/fimmu.2014.00659

M3 - Article

AN - SCOPUS:84926609176

VL - 6

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JAN

M1 - 00659

ER -